Log in with your email address username.


Attention doctorportal newsletter subscribers,

After December 2018, we will be moving elements from the doctorportal newsletter to MJA InSight newsletter and rebranding it to Insight+. If you’d like to continue to receive a newsletter covering the latest on research and perspectives in the medical industry, please subscribe to the Insight+ newsletter here.

As of January 2019, we will no longer be sending out the doctorportal email newsletter. The final issue of this newsletter will be distributed on 13 December 2018. Articles from this issue will be available to view online until 31 December 2018.

[Comment] Biodegradable polymer drug-eluting stents: caveat emptor

Percutaneous coronary intervention is one of the most widely done medical procedures worldwide. The success of this therapy has been largely dependent on the development of coronary stents, which enabled the procedure to become safer and more effective than balloon angioplasty alone.1 Drug-eluting stents, in particular, were a breakthrough technology. They facilitated the treatment of more complex disease patterns, previously not well managed by percutaneous intervention, because of a high rate of restenosis.